TP53 and hepatocellular carcinoma: Furthermore, in another prospective cohort study from the USA including 44 patients with advanced HCC who were treated with nivolumab, ctDNA profiling revealed somatic mutations in 93% of cases, with TP53 being the most frequently altered gene [68].